News &amp; Updates

Dapagliflozin helps prevent heart failure events, cardiovascular death

Treatment with dapagliflozin leads to a reduction in the rate of total heart failure (HF) events and cardiovascular death, irrespective of patient characteristics such as ejection fraction (EF), according to data from the DELIVER* trial.

Dapagliflozin helps prevent heart failure events, cardiovascular death

Dazodalibep reduces Sjögren’s syndrome-related symptoms

21 Jun 2023 by

Treatment with dazodalibep, a novel nonantibody fusion protein that acts as an antagonist of CD40 ligand, significantly reduced symptom burden in adults with Sjögren’s syndrome, according to the ALISS trial presented at EULAR 2023.

Dazodalibep reduces Sjögren’s syndrome-related symptoms

Romosozumab one-ups denosumab in boosting bone mineral density for chronic steroid users

In the treatment of chronic glucocorticoid users with high fracture risk, romosozumab yields higher gains in spine bone mineral density (BMD) compared with denosumab, as shown in a pilot trial presented at EULAR 2023.

Romosozumab one-ups denosumab in boosting bone mineral density for chronic steroid users

Visceral adipose tissue buildup tied to lower muscle density

Age-related accumulation of visceral adipose tissue (VAT) in both men and women may result in lower paraspinal muscle density, suggests a study.

Visceral adipose tissue buildup tied to lower muscle density

AI predicts early-stage rheumatoid arthritis using MRI scans

It is now possible to predict rheumatoid arthritis (RA), thanks to interpretations of magnetic resonance imaging (MRI) scans made by an artificial intelligence (AI) model.

AI predicts early-stage rheumatoid arthritis using MRI scans

20 Jun 2023

Which factors contribute to skin neoplasms in Lynch syndrome patients?

Individuals with Lynch syndrome (LS) often develop skin neoplasms, reports a recent study, which has identified several clinical factors that contribute to LS- and non-LS-related skin neoplasms.

Which factors contribute to skin neoplasms in Lynch syndrome patients?

Add-on mRNA cancer vaccine delivers promise for melanoma

Adding mRNA-4157, an investigational personalized neoantigen cancer vaccine, to the immune checkpoint inhibitor (ICI) pembrolizumab significantly improved recurrence-free survival (RFS) in individuals with resected high-risk melanoma, findings from the phase IIb KEYNOTE 942 study suggest.

Add-on mRNA cancer vaccine delivers promise for melanoma

20 Jun 2023

Mifepristone shows therapeutic promise in adenomyosis

Use of mifepristone in the treatment of patients with adenomyosis appears to be safe and efficacious, reducing pain and inducing dysmenorrhea remission, as reported in a study.

Mifepristone shows therapeutic promise in adenomyosis

Abatacept halts RA progression early in high-risk group